Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:50:53 2024-05-24 pm EDT 5-day change 1st Jan Change
11.69 USD +3.27% Intraday chart for Sage Therapeutics, Inc. -0.17% -46.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Sage Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained MT
Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q1 Revenue $7.9M, vs. Street Est of $5.2M MT
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sage Therapeutics, Inc. Announces Not Standing for Re-Election of Board of Directors CI
Sage Therapeutics, Inc. Announces Not Standing for Re-Election of Board of Directors CI
TD Cowen Cuts Sage Therapeutics Price Target to $16 From $30, Maintains Buy Rating MT
Scotiabank Cuts Price Target on Sage Therapeutics to $19 From $34, Maintains Sector Outperform Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $17 From $25, Maintains Perform Rating MT
Top Midday Decliners MT
BofA Securities Downgrades Sage Therapeutics to Underperform From Neutral, Adjusts Price Target to $14 From $24 MT
Sector Update: Health Care Stocks Advance Premarket Wednesday MT
Sector Update: Health Care MT
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday MT
Transcript : Sage Therapeutics, Inc. - Special Call
Top Premarket Decliners MT
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint MT
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease CI
JPMorgan Raises Price Target on Sage Therapeutics to $29 From $24, Maintains Overweight Rating MT
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board CI
Deutsche Bank Adjust Sage Therapeutics Price Target to $18 From $21, Maintains Hold Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $25 From $23, Maintains Perform Rating MT
RBC Raises PT on Sage Therapeutics to $26 From $21, Says Early Metrics From Zurzuvae Launch Suggest Promising Signs; Keeps Sector Perform, Speculative Risk MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday MT
Chart Sage Therapeutics, Inc.
More charts
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
11.32 USD
Average target price
22.24 USD
Spread / Average Target
+96.42%
Consensus
  1. Stock Market
  2. Equities
  3. SAGE Stock
  4. News Sage Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Advance Premarket Wednesday